Gemini Therapeutics, Inc. (NasdaqGM:GMTX) has initiated a process to evaluate strategic alternatives in order to maximize shareholder value. There can be no assurance that this strategic review process will result in the Company pursuing any transaction or that any transaction, if pursued, will be completed on attractive terms or at all. The Company has not set a timetable for completion of this strategic review process, and the Company does not intend to comment further unless or until its Board of Directors has approved a denitive course of action, the review process is concluded, or it is determined other disclosure is appropriate.